Stifel Nicolaus began coverage on shares of Repare Therapeutics (NASDAQ:RPTX) in a research report report published on Wednesday, Analyst Ratings Network reports. The firm issued a buy rating and a $48.00 target price on the stock.
Several other brokerages also recently weighed in on RPTX. Guggenheim initiated coverage on Repare Therapeutics in a research note on Monday, June 28th. They set a buy rating and a $46.00 target price for the company. Morgan Stanley raised their price objective on Repare Therapeutics from $45.00 to $47.00 and gave the stock an overweight rating in a research report on Monday, August 16th. Zacks Investment Research downgraded Repare Therapeutics from a hold rating to a sell rating in a research report on Saturday, September 11th. Finally, HC Wainwright initiated coverage on Repare Therapeutics in a research report on Monday, September 13th. They issued a buy rating and a $54.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Buy and a consensus price target of $47.33.
Shares of NASDAQ:RPTX opened at $27.63 on Wednesday. The business has a 50 day moving average price of $32.84 and a 200 day moving average price of $32.26. Repare Therapeutics has a twelve month low of $21.76 and a twelve month high of $46.44. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -13.35 and a beta of -0.35.
In related news, Director Orbimed Advisors Llc sold 7,082 shares of the firm’s stock in a transaction that occurred on Wednesday, August 25th. The stock was sold at an average price of $34.34, for a total transaction of $243,195.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Todd Foley sold 7,270 shares of the firm’s stock in a transaction on Monday, June 28th. The shares were sold at an average price of $34.18, for a total value of $248,488.60. The disclosure for this sale can be found here. Insiders have sold a total of 205,175 shares of company stock valued at $6,933,616 in the last 90 days. 33.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Morgan Stanley increased its holdings in Repare Therapeutics by 112.0% during the 2nd quarter. Morgan Stanley now owns 132,728 shares of the company’s stock valued at $4,138,000 after purchasing an additional 70,112 shares in the last quarter. Millennium Management LLC acquired a new stake in Repare Therapeutics during the 2nd quarter valued at $704,000. Price T Rowe Associates Inc. MD increased its holdings in Repare Therapeutics by 2,044.2% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,176,004 shares of the company’s stock valued at $36,668,000 after purchasing an additional 1,121,157 shares in the last quarter. Great Point Partners LLC acquired a new stake in shares of Repare Therapeutics in the 2nd quarter valued at $13,597,000. Finally, State Street Corp acquired a new stake in shares of Repare Therapeutics in the 2nd quarter valued at $470,000. 71.52% of the stock is owned by hedge funds and other institutional investors.
Repare Therapeutics Company Profile
Repare Therapeutics Inc, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.
Featured Article: What factors cause inflation to rise?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.